riluzole has been researched along with Brain Neoplasms in 7 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 7.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| "Current treatment for melanoma metastatic to the brain is grouped into those providing symptomatic relief such as corticosteroids and antiepileptic agents, to those that are disease modifying." | 6.52 | The current management of brain metastasis in melanoma: a focus on riluzole. ( Chen, S; Wall, BA; Yu, LJ, 2015) |
| "The riluzole treatment of all GBM cell lines mainly affected carbohydrate metabolism and the DNA structure." | 5.72 | Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment. ( Birarda, G; Dimitrijević, D; Dučić, T; Jover Mañas, GV; Martínez-Rovira, I; Ninkovic, M; Rohde, V; Sperling, S; Vaccari, L; Yousef, I, 2022) |
| "Riluzole-treated cells accumulate in G(2)/M phase of the cell cycle at 24 hours, and then undergo apoptotic cell death." | 5.37 | Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. ( Ahlawat, S; Chen, S; Goydos, JS; Green, C; Haffty, BG; Khan, AJ; Mehnert, JM; Schiff, D; Wall, B, 2011) |
| "In the present study, we investigated the effects of mGluR1 inhibition in human glioma U87 cells using specific targeted small interfering RNA (siRNA) or selective antagonists Riluzole and BAY36-7620." | 3.81 | Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway. ( Li, HY; Liao, YW; Liu, Q; Sang, SS; Su, J; Wang, XY; Yuan, XR; Zhang, C; Zhao, ZJ, 2015) |
| "Riluzole and memantine can be safely and effectively delivered intracranially via polymer in rat glioma models." | 3.80 | Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models. ( Blakeley, J; Brem, H; Gincel, D; Pardo, AC; Rothstein, JD; Tyler, B; Weaver, KD; Yohay, K, 2014) |
| "Current treatment for melanoma metastatic to the brain is grouped into those providing symptomatic relief such as corticosteroids and antiepileptic agents, to those that are disease modifying." | 2.52 | The current management of brain metastasis in melanoma: a focus on riluzole. ( Chen, S; Wall, BA; Yu, LJ, 2015) |
| "The riluzole treatment of all GBM cell lines mainly affected carbohydrate metabolism and the DNA structure." | 1.72 | Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment. ( Birarda, G; Dimitrijević, D; Dučić, T; Jover Mañas, GV; Martínez-Rovira, I; Ninkovic, M; Rohde, V; Sperling, S; Vaccari, L; Yousef, I, 2022) |
| "Riluzole-treated cells accumulate in G(2)/M phase of the cell cycle at 24 hours, and then undergo apoptotic cell death." | 1.37 | Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. ( Ahlawat, S; Chen, S; Goydos, JS; Green, C; Haffty, BG; Khan, AJ; Mehnert, JM; Schiff, D; Wall, B, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Dučić, T | 1 |
| Ninkovic, M | 1 |
| Martínez-Rovira, I | 1 |
| Sperling, S | 1 |
| Rohde, V | 1 |
| Dimitrijević, D | 1 |
| Jover Mañas, GV | 1 |
| Vaccari, L | 1 |
| Birarda, G | 1 |
| Yousef, I | 1 |
| Yamada, T | 1 |
| Tsuji, S | 1 |
| Nakamura, S | 1 |
| Egashira, Y | 1 |
| Shimazawa, M | 1 |
| Nakayama, N | 1 |
| Yano, H | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Yohay, K | 1 |
| Tyler, B | 1 |
| Weaver, KD | 1 |
| Pardo, AC | 1 |
| Gincel, D | 1 |
| Blakeley, J | 1 |
| Brem, H | 1 |
| Rothstein, JD | 1 |
| Wall, BA | 2 |
| Yu, LJ | 2 |
| Khan, A | 1 |
| Haffty, B | 1 |
| Goydos, JS | 2 |
| Chen, S | 3 |
| Zhang, C | 1 |
| Yuan, XR | 1 |
| Li, HY | 1 |
| Zhao, ZJ | 1 |
| Liao, YW | 1 |
| Wang, XY | 1 |
| Su, J | 1 |
| Sang, SS | 1 |
| Liu, Q | 1 |
| Khan, AJ | 1 |
| Wall, B | 1 |
| Ahlawat, S | 1 |
| Green, C | 1 |
| Schiff, D | 1 |
| Mehnert, JM | 1 |
| Haffty, BG | 1 |
1 review available for riluzole and Brain Neoplasms
| Article | Year |
|---|---|
The current management of brain metastasis in melanoma: a focus on riluzole.
Topics: Brain Neoplasms; Humans; Melanoma; Neuroprotective Agents; Riluzole | 2015 |
6 other studies available for riluzole and Brain Neoplasms
| Article | Year |
|---|---|
Live-Cell Synchrotron-Based FTIR Evaluation of Metabolic Compounds in Brain Glioblastoma Cell Lines after Riluzole Treatment.
Topics: Brain; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Riluzole; Spectroscopy, Fourier Tran | 2022 |
Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2020 |
Efficacy of local polymer-based and systemic delivery of the anti-glutamatergic agents riluzole and memantine in rat glioma models.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Drug Delivery Systems; Excitator | 2014 |
Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Clone Cells; Disease Models, Animal; Humans; Luciferases | 2015 |
Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Glioma | 2015 |
Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.
Topics: Animals; Apoptosis; Brain Neoplasms; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Survival; Combine | 2011 |